U lcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD) characterized by superficial mucosal ulceration, rectal bleeding, diarrhea, and abdominal pain. 1 Until the late 1990s, the therapeutic goal for UC was clinical remission as defined by symptom management. However, a growing body of evidence indicates that healing of the mucosa is an important therapeutic end point in clinical trials and in clinical practice. 2 This altered therapeutic paradigm has increased the role of endoscopy in UC further.
Colonoscopy with intubation of the terminal ileum is the standard of care for the diagnosis of patients with suspected UC. [3] [4] [5] Once the diagnosis is established, and when UC patients are included in clinical trials, endoscopy limited to the rectum and sigmoid is the standard to assess disease activity and endoscopic healing because it is believed that the most severe activity of UC is located in the distal colon. However, little evidence supports this assertion, and some UC patients may harbor more severe endoscopic inflammation proximal to the sigmoid colon.
Etrolizumab is a humanized monoclonal anti-b7 antibody with a dual mechanism of action, inhibiting both a4b7:MAdCAM-1-mediated lymphocyte trafficking to the gut mucosa and aEb7:E-cadherin-mediated lymphocyte retention in the intraepithelial compartment. [6] [7] [8] [9] [10] [11] [12] In a double-blind, placebo-controlled, randomized, phase 2 study, etrolizumab led to significantly greater rates of clinical remission at week 10 compared with placebo in patients with moderately to severely active UC. 13 During this study, 72% of endoscopic examinations assessed disease activity beyond the rectosigmoid. This circumstance allowed us to evaluate whether endoscopic assessment limited to the rectosigmoid adequately represents endoscopic activity of the more proximal colon, and how potential discrepancies might affect assessment of efficacy in the context of a randomized controlled clinical trial.
Materials and Methods

Patient Cohort
The EUCALYPTUS Q10 trial evaluated the efficacy and safety of etrolizumab (Genentech, South San Francisco, CA) in patients with moderately to severely active UC, who had not responded to conventional therapy, including immunosuppressants and/ or at least one anti-tumor necrosis factor agent. For this randomized, double-blind, placebo-controlled, multicenter, phase 2 study, patients were recruited from 40 centers in 11 countries. Of 124 patients, 41 patients were assigned to 100-mg etrolizumab administered subcutaneously at weeks 0, 4, and 8; 40 patients were assigned to 300-mg etrolizumab at weeks 2, 4, and 8, plus a 420-mg loading dose administered between weeks 0 and 2; and 43 patients were assigned to monthly subcutaneous injections of placebo for 3 months. Five patients were excluded from the modified intent-to-treat population because they had a centrally read screening endoscopic subscore of less than 2, leaving 41 analyzed from the placebo group, 39 from the 100-mg etrolizumab group, and 39 from the 300-mg etrolizumab plus loading dose group. Details of patient demographics, methods, and eligibility criteria have been described previously. 13 Briefly, patients included were adults diagnosed with UC for a minimum of 12 weeks, who had a Mayo Clinic Score 14 (MCS) of 5 or greater, with an MCS endoscopic subscore (MCSe) of 2 or greater, a rectal bleeding symptom score of 1 or greater, and disease extending 25 cm or more from the anal verge. The primary efficacy end point was clinical remission at week 10, defined as the proportion of patients with an MCS of 2 or less, with no individual subscore greater than 1. The post hoc analyses described here received institutional review board approval under the EUCALYPTUS protocol (ClinicalTrials.gov, NCT01336465).
Analysis of Endoscopic Examinations
The current study examined 331 videos of endoscopies captured during the EUCALYPTUS trial, after exclusion of videos without associated patient identification numbers and videos of patients excluded because of protocol violations ( Supplementary Figures 1 and 2) . Videos of patient endoscopies were recorded at the baseline screening visit (week 0), and after randomization at week 6 and week 10. Of the 331 videos, 239 (100 from baseline and 139 from weeks 6 and 10) included assessment of colonic segments proximal to the rectosigmoid region, and were analyzed for disease activity and endoscopic healing in this study (Supplementary Figure 2) . Endoscopic severity was assessed using the MCSe and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). 15, 16 For the MCSe, active disease was defined as a score greater than 1, and endoscopic healing was defined as MCSe of 1 or less or MCSe of 0. We included analyses with endoscopic healing defined as MCSe of 0 because of emerging evidence that a score of 0 may be linked to different patient outcomes compared with a score of 1. 17 Currently, the UCEIS does not specify a cut-off score to distinguish active disease from endoscopic healing and, therefore, was not used to calculate positive predictive values (PPV) and negative predictive values.
Central readers performed a preliminary evaluation of videos to determine parameters for scoring the MCSe and the UCEIS. Of note, the location of segments explored was not annotated on the videos during recording and not all patients received full colonoscopies with examination of all 5 colonic segments (rectum, sigmoid, descending colon, transverse colon, and ascending colon). Four central readers (2 per video) from 2 sites estimated the number of colonic segments examined, guided by the length of the segments and identification of anatomic characteristics such as the hepatic, splenic, and rectosigmoid flexures. Readers also determined the extent of disease.
For determining endoscopic healing based on the MCSe, the worst score of the rectosigmoid alone was compared with the worst score of the whole colon (including the rectosigmoid). A separate, independent, central reader adjudicated the final score when discrepancies emerged between the 2 readers of the same video.
For the analysis of individual endoscopic severity scores (Figure 1 ), all 331 videos were scored with both the MCSe and the UCEIS, with 2 reads per video (1 from each reader, without adjudication; 662 reads). Reads with 2 or fewer segments were excluded (251), resulting in a total of 411 reads (Supplementary Figure 1) . The rectosigmoid and the proximal colon (descending, transverse, and ascending colon) were scored separately, according to the worst-affected segment. Each component of the UCEIS (vascular pattern, bleeding, and erosions and ulcers
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) was scored separately. The total UCEIS scores were generated from each reader from the sum of their respective subscores.
Statistical Analysis
To determine the level of correlation between rectosigmoidoscopy and colonoscopy for detecting disease activity and endoscopic healing, contingency tables were generated that tabulated the number of adjudicated MCSe scores above and below the indicated MCSe cut-off values. The degree of intermethod agreement and correlation was determined by the calculation of the kappa coefficient (k) and the Spearman correlation coefficient (r) for each contingency table, respectively. The interpretation of the k and the correlation coefficients was based on the proposed cut-off values by Landis and Koch, 18 who recommended the following standards for strength of agreement for the k coefficient: 0, poor; 0.01-0.20, slight; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, substantial; and 0.81-1, nearly perfect. Negative predictive values and PPVs also were calculated. P values were based on the 2-sided Fisher exact test. Because this analysis was retrospective and not a prespecified goal of the EUCALYPTUS protocol, formal sample size calculations were not performed.
Results
Number of Bowel Segments Evaluated and Description of Disease Extent
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Comparable numbers of videos were examined at each visit for each treatment group (Table 1) . Across the 3 treatment groups, the average number of total segments examined was 3.2, and the number of segments examined across different visits (weeks 0, 6, and 10) and between treatment groups did not differ significantly.
Across all treatment groups, 25% of patients had UC limited to the rectosigmoid region and 75% of patients had disease in the proximal colon, defined as any region beyond the rectosigmoid (Table 2) .
Overall Evaluation
Among all of the videos, regardless of the number of segments read, 67 videos (67 of 354; 19%) were sent for adjudication. Among videos with more than 2 segments, 55 videos (55 of 239; 23%) were sent for adjudication. The MCSe in videos in which only 2 segments or fewer were examined (mean ± SD, 2.66 ± 0.63) did not differ significantly from videos with more than 2 segments examined (mean ± SD, 2.54 ± 0.75) (Supplementary Table 1) .
Across all visits and examinations, 239 videos examined colonic segments proximal to the rectosigmoid. For 230 videos, rectosigmoidoscopy and colonoscopy analyses agreed, determining that active disease (MCSe 2) was present in 205, but absent in 25 videos (Table 3 , left). There was a strong correlation between the scores based on the 2 techniques (k ¼ 0.83; r ¼ 0.84). However, for 9 of the 239 videos, the scores were discordant in assessing active disease, for example, rectosigmoidoscopy found evidence of endoscopic healing, but examination of the more proximal colon with colonoscopy found mucosal lesions (MCSe 2). These 9 videos came from 7 patients: 3 with left-sided colitis, 2 with pancolitis, 1 with disease previously limited to the rectosigmoid, and 1 in whom the previous extent of disease was not specified. If endoscopic healing was defined as MCSe of 0 and endoscopic activity was defined as MCSe of 1 or more, the concordance between rectosigmoidoscopy and colonoscopy increased (k ¼ 0.95; r ¼ 0.96), because only 1 video showed endoscopic healing in the rectosigmoid whereas significant mucosal lesions were found in the proximal colon (Table 3, right) .
We then analyzed whether the severity of disease differed in the proximal colon compared with the rectosigmoid, using both the MCSe and the UCEIS (Figure 1 and Supplementary Figure 3) . For this analysis, each region was scored separately and there was no adjudication between readers; each score given by the readers was considered an individual piece of data. In general, we observed more severe disease in the rectum and sigmoid according to the MCSe, but 19 of the 411 (4.6%) individual reads with more than 2 segments showed greater disease severity in the proximal colon than in the rectosigmoid region ( Figure 1A , gray cells). Of those 19 scores, 14 (rectosigmoid 1, proximal colon 2) affected the assessment of endoscopic healing in the colon. In addition, assessment of endoscopic disease using the UCEIS confirmed the presence of more severe disease in the rectosigmoid compared with the proximal colon (3.98 ± 1.82 vs 2.38 ± 1.98; P < .0001), but in a small proportion of the videos (31 of 411; 7.5%), more severe disease was found in the proximal colon. Scoring with the UCEIS, using both the total UCEIS and individual subscores, also showed a high correlation between rectosigmoidoscopy and colonoscopy (r ¼ 0.92) ( Figure 1B 
Evaluation of Endoscopic Activity at Baseline
When we assessed endoscopic activity (MCSe 2) at baseline, we observed a moderate agreement/correlation (k ¼ 0.49, r ¼ 0.57) between the scores based on rectosigmoidoscopy and colonoscopy (Table 4 ). This level of correlation was related to the highly skewed distribution of MCSe values toward scores of 2 and 3, given the study inclusion criteria. In 2 of 100 videos performed at baseline, rectosigmoidoscopy failed to find active disease whereas colonoscopy showed active disease above the sigmoid colon.
Evaluation of Endoscopic Healing
After treatment with etrolizumab, patients then were assessed for endoscopic healing (MCSe 1) at weeks 6 and 10 using a total of 139 available videos (Table 5 , left). Although 31 videos showed endoscopic healing in the rectum and sigmoid colon, only 24 also had healing in the proximal colon, a difference of approximately 23% (PPV for endoscopic healing by rectosigmoidoscopy, 0.77). Colonoscopy and rectosigmoidoscopy showed a high correlation for the detection of endoscopic healing (k ¼ 0.84; r ¼ 0.85).
With endoscopic healing defined as MCSe of 0 at weeks 6 and 10 (Table 5 , right), 12 videos showed healing in the rectum and sigmoid colon. Only 1 video did not show endoscopic healing in the proximal colon, a difference of approximately 9%. Therefore, when endoscopic healing was defined as an MCSe of 0, the correlation between the 2 techniques was very strong (k ¼ 0.95; r ¼ 0.95), and rectosigmoidoscopy was better able to predict endoscopic healing (PPV, 0.92) in the proximal colon.
When we investigated the efficacy of etrolizumab using rectosigmoidoscopy, we found that there was a trend toward higher rates of endoscopic healing, but there was no significant treatment effect for either dose group over placebo by weeks 6 and 10 ( Figure 2, white bars) . Colonoscopy also showed no significant treatment effect at week 6 ( Figure 2A) . However, at week 10, colonoscopy determined that the proportion of patients with endoscopic healing in the placebo group was 8%, rather than 14%, the proportion measured by rectosigmoidoscopy ( Figure 2B ). Although this difference did not affect the efficacy assessment for the 300-mg dose group, this lower percentage of patients with healing increased the effect size to a significant level between the placebo and the 100-mg etrolizumab treatment groups (P ¼ .035).
Discussion
In general, when we compared the ability of rectosigmoidoscopy with colonoscopy for determining either the presence of active disease or endoscopic healing in patients with moderately to severely active UC, we found strong correlations between the 2 examinations. Rectosigmoidoscopy was able to detect active disease reliably at the inclusion of patients in the study. We also found that the most severe disease was located more frequently in the rectosigmoid colon, a relevant finding for clinical practice because therapeutic decisions are based not only on the presence of active disease but also on severity.
The ability of rectosigmoidoscopy to detect disease activity compared with colonoscopy differed between baseline and post-treatment at week 6 and week 10. At baseline, rectosigmoidoscopy accurately reflected disease activity in the whole colon. In contrast, at weeks 6 and 10, when endoscopic healing was defined as MCSe of 1 or less, rectosigmoidoscopy indicated healing of the distal mucosa, although there was evidence of mucosal ulceration more proximally on colonoscopy. This resulted in a placebo remission rate that was almost 2-fold higher based on rectosigmoidoscopy compared with colonoscopy (14% vs 8%, respectively) ( Figure 2B ), and a decreased treatment effect size. However, when endoscopic healing was defined as MCSe of 0, concordance improved between rectosigmoidoscopy and colonoscopy, because only 1 of 11 videos had discordant scores between the 2 techniques (Table 5, right). n, number of videos evaluated; LD, loading dose. n, number of patients.
According to guidelines and consensus panels, once the diagnosis is established, rectosigmoidoscopy alone is usually sufficient to assess endoscopic activity/severity in the management of UC. [3] [4] [5] Few studies, however, and none in the context of a therapeutic trial, have formally compared endoscopic severity in the rectosigmoid vs the whole colon. In a retrospective analysis of medical charts and endoscopic images from 545 UC patients, Kato et al 19 determined the colonic locations of the maximum inflammatory activity. Although the majority of the patients analyzed (73%) had maximum inflammation in the rectum and sigmoid, 27% had maximum activity proximal to the sigmoid, in the descending colon, or in segments proximal to the splenic flexure. In addition, they found that 40% of patients had inflamed mucosa in the descending colon or in the more proximal portion of the colon, but showed no inflammation in the rectum and sigmoid. They concluded that total colonoscopy was warranted in patients who have a discrepancy between their symptoms and rectosigmoidoscopy results. A caveat of this study was that the use of rectal therapy with mesalazine or steroids was allowed. In the EUCALYPTUS trial, rectal therapy was withdrawn 2 weeks before randomization and concomitant use of rectal therapy was contraindicated during the treatment phase of the trial because of the possibility of rectal sparing. 20 In this endoscopy study, we used the UCEIS in addition to the MCSe to compare disease severity in the rectosigmoid and the proximal colon. We were unable to use the UCEIS to assess the end points of disease activity or endoscopic healing because a threshold score for mucosal healing has not yet been established. 16 In general, the UCEIS confirmed the MCSe findings of more severe disease in the rectosigmoid for all 3 subscores (Supplementary Figure 3) and for the overall score ( Figure 1B) . The UCEIS, as with the MCSe, also detected a small, but slightly higher, proportion of videos in which proximal disease was more severe than in the rectosigmoid (7.5% vs 4.6% for the MCSe) (Figure 1 ), and showed a very high correlation between rectosigmoidoscopy and colonoscopy.
One limitation of our study was that only 239 of 331 examinations progressed beyond the sigmoid colon. There may be some concern that the reasons for the unavailability of colonoscopy in those patients may have introduced bias into the study. Patients with severe disease above the sigmoid may have been underestimated because of concerns by the endoscopist in proceeding with the examination beyond the sigmoid colon. However, the number of segments analyzed between treatment groups was similar (Table 1 ) and disease severity (mean MCSe) also was similar between videos with fewer than 2 and those with more than 2 segments (Supplementary Table 1) , which rules out a bias arising from performing rectosigmoidoscopy or colonoscopy based on the endoscopic severity of the disease. Another potential limitation was that because the explored segments were not annotated in the videos, the readers identified segments based on anatomic characteristics and the length of the segment; in particular, the boundary between the descending colon and the sigmoid could be difficult to distinguish, even for skilled endoscopists. However, it is unlikely that this would have affected the evaluation of the rectosigmoid significantly compared with the whole colon. We also acknowledge that, in this trial, the number of MCSe scores in which the proximal colon had more severe disease than the rectosigmoid (9 of 239) was low. However, the number of patients who typically achieve remission in induction studies is also low, which means that factors that influence placebo rates can have a direct effect on statistical significance and influence decisions about the further development of experimental therapies. Finally, because this NOTE. This analysis only included assessments with more than 2 segments and all visits were pooled. CI, confidence interval; n, number of videos evaluated; N, no; NPV, negative predictive value; R/S, rectosigmoidoscopy; Y, yes. a Number of discordant scores for endoscopic activity that were affected when the proximal colon was included in the evaluation. Presence of endoscopically active disease (MCSe 2, left; MCSe 1, right). NOTE. This analysis only included assessments with more than 2 segments. CI, confidence interval; n, number of videos evaluated; N, no; NPV, negative predictive value; R/S, rectosigmoidoscopy; Y, yes. a Number of scores for endoscopic activity that were affected when the proximal colon was included in the evaluation. Presence of endoscopically active disease (MCSe 2).
was an induction study, we cannot extrapolate these findings to maintenance studies. Longer treatment duration with therapies that are effective may improve the concordance between rectosigmoidoscopy and colonoscopy, and consequently show that rectosigmoidoscopy is sufficient for measuring clinical effectiveness in maintenance trials.
Despite these limitations, this study has important implications for the use of rectosigmoidoscopy and/or colonoscopy in both clinical practice and during clinical trials. Because of its strong ability to detect active disease, rectosigmoidoscopy should be sufficient in clinical practice for evaluating previously diagnosed patients with new symptoms. Two notable exceptions may be pediatric patients and patients with primary sclerosing cholangitis in whom relative or complete rectal sparing has been observed. 21, 22 However, in cases in which rectosigmoidoscopy has detected endoscopic healing in response to induction therapy, but symptoms persist, performance of a more extensive examination with colonoscopy is justified. In the clinical trial setting, this study suggests that if endoscopic healing is defined as an MCSe of 0, rectosigmoidoscopy is sufficient for efficacy analyses. However, if endoscopic healing is defined as an MCSe of 1 or less, these preliminary data suggest that colonoscopy is better than rectosigmoidoscopy for assessing the full extent of endoscopic healing for efficacy analyses of experimental therapies. Colonoscopy is more expensive than rectosigmoidoscopy because it frequently requires sedation and bowel preparation, which, in turn, may impose additional burdens on the patient, such as missing work and requiring a caregiver to transport the patient to and from the endoscopy suite. The balance between cost and performance is an important consideration and is most relevant in the development of experimental therapies. It may be preferable to use full colonoscopy in relatively small phase 2 induction studies. However, these results warrant further evaluation prospectively in a larger study before colonoscopy can be recommended for standard use in clinical trials. NOTE. This analysis only included assessments with more than 2 segments by visit (excluding the screening visit). CI, confidence interval; n, number of videos evaluated; N, no; NPV, negative predictive value; R/S, rectosigmoidoscopy; Y, yes. a Number of scores for endoscopic healing that were affected when the proximal colon was included in the evaluation. Presence of endoscopic healing (MCS 1, left; MCSe ¼ 0, right). 721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780   781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839 841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891  892  893  894  895  896  897  898  899  900   901  902  903  904  905  906  907  908  909  910  911  912  913  914  915  916  917  918  919  920  921  922  923  924  925  926  927  928  929  930  931  932  933  934  935  936  937  938  939  940  941  942  943  944  945  946  947  948  949  950  951  952  953  954  955  956  957  958 1 (1) 3 (1) n, number of videos evaluated; N/A, not applicable. 1201  1202  1203  1204  1205  1206  1207  1208  1209  1210  1211  1212  1213  1214  1215  1216  1217  1218  1219  1220  1221  1222  1223  1224  1225  1226  1227  1228  1229  1230  1231  1232  1233  1234  1235  1236  1237  1238  1239  1240  1241  1242  1243  1244  1245  1246  1247  1248  1249  1250  1251  1252  1253  1254  1255  1256  1257  1258  1259  1260   1261  1262  1263  1264  1265  1266  1267  1268  1269  1270  1271  1272  1273  1274  1275  1276  1277  1278  1279  1280  1281  1282  1283  1284  1285  1286  1287  1288  1289  1290  1291  1292  1293  1294  1295  1296  1297  1298  1299  1300  1301  1302  1303  1304  1305  1306  1307  1308  1309  1310  1311  1312  1313  1314  1315  1316  1317  1318  1319  1320 
